Aligos Therapeutics (ALGS) Enterprise Value (2020 - 2026)

Aligos Therapeutics (ALGS) has reported Enterprise Value for 7 consecutive years, with $29.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 119.5% year-over-year to $29.7 million; the trailing twelve-month figure through Jun 2026 stood at $29.7 million (up 119.5% YoY), and the FY2025 full-year result was $14.3 million, down 92.59% from the prior year.
• Enterprise Value advanced to $29.7 million in Q2 2026 per ALGS's latest filing, from -$2.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at $3.6 billion in Q1 2024 and bottomed at -$152.6 million in Q2 2025.
• Historically, Enterprise Value has averaged $740.8 million across 5 years, with a median of $788.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 334.21% in 2024, then tumbled 112.45% in 2025.
• Over 5 years, Enterprise Value stood at $897.0 million in 2022, then grew by 3.78% to $930.9 million in 2023, then slumped by 79.31% to $192.6 million in 2024, then tumbled by 92.59% to $14.3 million in 2025, then surged by 108.23% to $29.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $29.7 million, -$2.5 million, and $14.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.